MedTrace Logo

Radiotherapy or Imiquimod in Complex Lentigo Maligna

NCT02394132 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2024-06-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the effectiveness of using either radiotherapy (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is refused, or fails.

Conditions

  • Lentigo Maligna

Interventions

DRUG

Imiquimod

RADIATION

Radiotherapy

Sponsors & Collaborators

  • Melanoma Institute Australia

    collaborator OTHER

  • Melanoma and Skin Cancer Trials Limited

    lead OTHER

Principal Investigators

  • Pascale Guitera · Melanoma Institute Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2021-12-24
Completion
2023-03-30

Countries

  • Australia
  • Brazil
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02394132 on ClinicalTrials.gov